UBS reduces the target price on Regeneron Pharmaceuticals, Inc. (RegN).

Regeneron Pharmaceuticals, Inc. (Nasdaq:rainFrom among 11 best genome stocks to buy according to hedge boxes. UBS maintained its neutral classification on Regeneon Pharmaceuticals, Inc. (NASDAQ: RegN) and reduced its goal from $ 633 to $ 560 on June 5, indicating the updates of mixed companies and modern pipeline developments.

A pharmacist in the laboratory coat carefully analyzes the medicine bottle for its quality.

Stage 2 of the temporary reading study of stage 2, which are the results of the 3/2 stage experiments for Itepekimab in chronic obstructive pulmonary disease, acquisition of 23ndme of $ 256 million, and a license agreement with Hansoh to obtain the previous rights of China in the 3 GLP-1/GIP GIP receptors are among the notes that are noticeable. Ubs Receneron Pharmaceuticals, Inc. (NASDAQ: RegN) The continuous continuous Eylea Eylea weaken as a big problem in the short term.

Modern strategic procedures are shown by Regeneron Pharmaceuticals, Inc. However, due to the difficulties facing Eylea concession, market morale is still cautious.

Although pipeline updates, such as data from the experience of chronic obstructive pulmonary disease and the partnership of representative assets with Hansoh, have long -term capabilities, UBS believes that these benefits outweigh the pressure from the current privileges, which support the updated goal of the target and the neutral position.

While we acknowledge the capabilities of RGN as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 10 high -growth shares EV to invest in them and 13 best car shares to buy in 2025.

Detection. no one.